Topics
ArticleOrgan chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
ArticleAI’s real value in drug discovery may be choosing the right experiment
AI is becoming more capable, but its value still depends on the data, questions and decisions behind it. Where is it genuinely improving drug discovery and where do the limitations remain?
ArticleFrom R&D to QC: building a single analytical strategy for cell and gene therapies
From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?
InterviewThe global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
WebinarWhat it takes to automate high-content imaging at scale
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
WebinarThe truth about AI in drug discovery: what the experts really think
AI is transforming drug discovery - but beyond the hype, what’s actually delivering results? In this expert-led webinar, industry leaders explore where AI is accelerating target identification, molecule design and hit discovery, while also confronting the real-world challenges of data quality, validation and adoption. Discover what’s working today, what still ...
WebinarCan One Peptide Change Pain Research? Meet the Tool Transforming Drug Discovery
Discover how a new peptide tool, WRPRFa, is helping researchers better understand pain pathways and accelerate the search for next-generation analgesics.
WebinarOvercoming Affinity and Expression Bottlenecks in TCR Discovery
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
ArticleSynthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
ArticleAntibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
ArticleCerebral organoids reveal how Ebola virus persists in neural tissue
How does Ebola virus survive long after recovery? A new study using human cerebral organoids explores viral persistence in neural tissue and the growing role of organoid models in drug discovery research.
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a new approach for treating cardiovascular disease.
- Article
Synthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
- Article
Organ chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
- Article
AI’s real value in drug discovery may be choosing the right experiment
AI is becoming more capable, but its value still depends on the data, questions and decisions behind it. Where is it genuinely improving drug discovery and where do the limitations remain?
- Article
From R&D to QC: building a single analytical strategy for cell and gene therapies
From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?
- Article
Synthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
- Article
Organ chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
- Article
Antibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
- Interview
The global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
- Article
Synthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
- Article
Organ chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
- Article
From R&D to QC: building a single analytical strategy for cell and gene therapies
From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?
- Article
Antibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
ArticleDrug development has changed. Bioanalysis is changing with it
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
NewsEuropean initiative aims to bring molecular dynamics into mainstream drug discovery
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
ReportAI in Drug Discovery: Progress, Limits and What Comes Next
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
ArticleWhy targeted therapies are exposing the limits of animal models – and what comes next
Traditional preclinical models are struggling to keep pace with a new generation of targeted therapies. As regulators embrace new approach methodologies (NAMs), vascularised tissue platforms are offering a more human-relevant approach to predicting drug efficacy and safety.